Last reviewed · How we verify
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.
Details
| Lead sponsor | Incyte Corporation |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 29 |
| Start date | Thu May 31 2007 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Apr 30 2009 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Psoriasis
Interventions
- Ruxolitinib phosphate cream
- Dovonex® calcipotriene 0.005%
- Diprolene® AF betamethasone dipropionate 0.05% cream.
- Placebo cream
- Ruxolitinib phosphate cream
- Ruxolitinib phosphate cream
Countries
United States